Morgan Stanley maintains CMS Energy (NYSE:CMS) with a Equal-Weight and raises the price target from $60 to $64.
Traders Circulate Post Suggesting Novartis AG ‘Misses On 2nd Interim For NATALEE Trial. Not A Good Sign For Differentiation Vs Abema’
https://twitter.com/pharmacreep/status/1612487217800167424